Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 17/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 17/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14692500 | 0.86 | GABRA2 (0.51) | GABRA2GABRB2GAACYP1A2PDE4B | |
| SCHEMBL9894021 | 0.82 | GABRA2 (0.43) | GABRA2GABRB2GAACYP1A2 | |
| SCHEMBL1442132 | 0.81 | GABRA2 (0.42) | GABRA2GABRB2GAA | |
| SCHEMBL1437310 | 0.81 | GABRA2 (0.69) | GABRA2GABRB2 | |
| SCHEMBL1438374 | 0.80 | GABRA2 (0.66) | GABRA2GABRB2CYP1A2 | |
| SCHEMBL9894431 | 0.79 | TGFBR1 (0.57) | GABRA2GABRB2GAACYP1A2 | |
| SCHEMBL9893664 | 0.79 | GABRA2 (0.54) | GABRA2GABRB2 | |
| SCHEMBL9894373 | 0.78 | MDM2 (0.39) | GABRA2GABRB2CYP1A2PDE4B | |
| SCHEMBL1437424 | 0.78 | GABRA2 (0.67) | GABRA2GABRB2 | |
| SCHEMBL1437375 | 0.77 | MDM2 (0.45) | GABRA2GABRB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | GABRA2 4293/4885GABRB2 4278/4885GAA 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.